{
    "clinical_study": {
        "@rank": "60400", 
        "arm_group": [
            {
                "arm_group_label": "A (PEG-IFN-SA /RBV low dose)", 
                "arm_group_type": "Experimental", 
                "description": "PEG-IFN-SA 0.75\u03bcg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),\uff08BW\uff1c75kg\uff0c1000mg/d\uff1bBW\u226575kg\uff0c1200mg/d\uff09"
            }, 
            {
                "arm_group_label": "B (PEG-IFN-SA /RBV middle dose)", 
                "arm_group_type": "Experimental", 
                "description": "PEG-IFN-SA 1.5\u03bcg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),\uff08BW\uff1c75kg\uff0c1000mg/d\uff1bBW\u226575kg\uff0c1200mg/d\uff09"
            }, 
            {
                "arm_group_label": "C (PEG-IFN-SA /RBV high dose)", 
                "arm_group_type": "Experimental", 
                "description": "PEG-IFN-SA 2.0\u03bcg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),\uff08BW\uff1c75kg\uff0c1000mg/d\uff1bBW\u226575kg\uff0c1200mg/d\uff09"
            }, 
            {
                "arm_group_label": "D (Pegasys /RBV)", 
                "arm_group_type": "Active Comparator", 
                "description": "Pegasys 180\u03bcg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),\uff08BW\uff1c75kg\uff0c1000mg/d\uff1bBW\u226575kg\uff0c1200mg/d\uff09"
            }
        ], 
        "brief_summary": {
            "textblock": "This dose-escalating study is to evaluate the efficacy and the safety of different doses of\n      a new bio-product Pegylated Recombinant Consensus Interferon Variant Solution for Injection\n      (PEG-IFN-SA) and Ribavirin\uff08RBV\uff09 in the treatment of Chronic hepatitis C who have not been\n      previously treated with Interferon(IFN) by exploring the dose-effect relationship, while\n      identity the optimal dose for phase \u2162 study. In addition, population pharmacokinetic method\n      is adopted to assess the pharmacokinetic behavior, individuals / intra-individual\n      variability, and the possible factors for further study."
        }, 
        "brief_title": "A Phase \u2161 Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis C", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Total 200 subjects will be randomized and enrolled into four groups proportionally receiving\n      experimental drug of high dose, middle dose, low dose and positive-control drug.  Treatment\n      duration will be 24 or 48 weeks corresponding to different HCV genotype, genotype 2,3 and\n      non-genotype2,3."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18- 65 years\n\n          -  Body Mass Index (BMI) 18-30\n\n          -  Chronic hepatitis C , diagnosed according to Chinese guideline of Hepatitis C (year\n             2004)\n\n          -  Detectable serum HCV-RNA by quantitative polymerase chain reaction assay and positive\n             anti-HCV antibody\n\n          -  Female subjects of childbearing age with no history of menopause and negative\n             pregnancy test, both female and male( including their partners ) subjects were\n             required to conduct adequate contraception since screening until the 6 months after\n             treatment\n\n          -  Volunteered to participate in this study, understood and signed an informed consent\n\n        Exclusion Criteria:\n\n          -  Previous IFN treated patients\n\n          -  Co-infection with HAV, HBV, HEV, EBV, CMV and HIV\n\n          -  Evidences of hepatic decompensation, including but not limited to serum total\n             bilirubin> 2 times the upper limit of normal (ULN); serum albumin <35g/L; prothrombin\n             activity (PTA) <60%; ascites, upper gastrointestinal bleeding and hepatic\n             encephalopathy; Child-Pugh score B/C grade\n\n          -  Hepatotoxic drugs was used for a long time within past 6 months\n\n          -  Diagnosed with primary hepatocellular carcinoma or supported by evidences including\n             but not limited to AFP> l00ng/ml, suspicious liver nodules by imaging examinations\n\n          -  Liver diseases from causes other than HCV infection, including alcoholic liver\n             disease, non-alcoholic steatohepatitis, drug-induced hepatitis, autoimmune hepatitis\n             (antinuclear antibody titer higher than 1:100), hepatolenticular degeneration\n             (Wilson's disease) and hemochromatosis, etc.\n\n          -  White blood cell count <3\u00d7109/L; Neutrophil count<1.5\u00d7109/L; platelet count<90\u00d7109/L;\n             hemoglobin below the lower limit of normal\n\n          -  Serum creatinine not within the normal range\n\n          -  Serum creatine kinase> 3 ULN\n\n          -  Positive thyroid antibodies (A-TPO, A-TG)\n\n          -  Therapy with potent immunomodulatory agents such as adrenocorticotropic hormone,\n             thymosin \u03b11 etc. within past 6 months or an anticipated usage during the period of\n             study\n\n          -  Allergies or severe allergies, especially allergic to study drugs or any ingredients\n             of the study drugs\n\n          -  Severe autoimmune diseases; psychiatric and nervous system disorders, including\n             history of Psychiatric illness or with family history (especially depression,\n             depressive tendencies, epilepsy and hysteria, etc.); Serious blood disorders (all\n             kinds of anemia, hemophilia, etc.); Severe kidney disease (chronic kidney disease,\n             renal insufficiency, etc.); poorly controlled digestive diseases; endocrine disorders\n             such as thyroid disease and diabetes; severe respiratory disease (pneumonia, chronic\n             obstructive pulmonary disease, interstitial lung disease, etc.); cardiovascular\n             diseases (hypertension, uncontrolled coronary atherosclerotic heart disease, heart\n             failure, etc.); retinal disease; malignancies; or unsuitable for study considered by\n             clinician\n\n          -  Function organs transplant\n\n          -  Evidence of alcohol or drug abuse (average alcohol consumption male> 40g / day,\n             female> 20g / day)\n\n          -  Pregnant or lactating women\n\n          -  Usage of prohibition drugs in this study\n\n          -  Participated in other clinical trials 3 months prior to the screening\n\n          -  Unwilling to sign the informed consent and adhere to treatment requirements\n\n          -  Other conditions not suitable for study judged by investigators"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01908335", 
            "org_study_id": "KAWIN-002-1"
        }, 
        "intervention": [
            {
                "arm_group_label": "A (PEG-IFN-SA /RBV low dose)", 
                "description": "24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3", 
                "intervention_name": "PEG-IFN-SA /RBV low dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "B (PEG-IFN-SA /RBV middle dose)", 
                "description": "24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3", 
                "intervention_name": "PEG-IFN-SA /RBV middle dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "C (PEG-IFN-SA /RBV high dose)", 
                "description": "24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3", 
                "intervention_name": "PEG-IFN-SA /RBV high dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "D (Pegasys /RBV)", 
                "description": "24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3", 
                "intervention_name": "Pegasys /RBV", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferons", 
                "Ribavirin", 
                "Interferon alfacon-1", 
                "Peginterferon alfa-2a"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "interferon", 
            "ribavirin", 
            "virological response"
        ], 
        "lastchanged_date": "July 23, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Lanzhou", 
                        "country": "China", 
                        "state": "Gansu"
                    }, 
                    "name": "First Affiliated Hospital of Lanzhou University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong"
                    }, 
                    "name": "Guangzhou Eighth People's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong"
                    }, 
                    "name": "Nanfang Hospital Southern Medical Unbiversity"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong"
                    }, 
                    "name": "Guangdong General Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shenzhen", 
                        "country": "China", 
                        "state": "Guangdong"
                    }, 
                    "name": "The third people's hospital of Shenzhen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanning", 
                        "country": "China", 
                        "state": "Guangxi"
                    }, 
                    "name": "The First Affiliated Hospital of Guangxi Medical University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shijiazhuang", 
                        "country": "China", 
                        "state": "Hebei"
                    }, 
                    "name": "Third Affiliated Hospital, Hebei Medical University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Harbin", 
                        "country": "China", 
                        "state": "Heilongjiang"
                    }, 
                    "name": "The First Affiliated Hospital of Harbin Medical University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zhengzhou", 
                        "country": "China", 
                        "state": "Henan"
                    }, 
                    "name": "Henan Provincial People's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China", 
                        "state": "Hubei"
                    }, 
                    "name": "Union hospital, Tongji Medical College Huazhong University of Science \uff06 Technology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China", 
                        "state": "Hubei"
                    }, 
                    "name": "Tongji Hospital, Tongji Medical College Huazhong University of Science \uff06 Technology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China", 
                        "state": "Hubei"
                    }, 
                    "name": "Zhongnan Hospital of Wuhan University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changsha", 
                        "country": "China", 
                        "state": "Hunan"
                    }, 
                    "name": "The Second Xiangya Hospital of Central South University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China", 
                        "state": "Jiangsu"
                    }, 
                    "name": "The Second Hospital of Nanjing"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changchun", 
                        "country": "China", 
                        "state": "Jilin"
                    }, 
                    "name": "The First Affiliated Hospital of Jilin University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shenyang", 
                        "country": "China", 
                        "state": "Liaoning"
                    }, 
                    "name": "The Sixth People's Hospital of Shenyang"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Xi'an", 
                        "country": "China", 
                        "state": "Shaanxi"
                    }, 
                    "name": "Tangdu Hospital , , Fourth Military Medical University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Xi'an", 
                        "country": "China", 
                        "state": "Shaanxi"
                    }, 
                    "name": "First Affiliated Hospital Of Medical College of Xian Jiaotong University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jinan", 
                        "country": "China", 
                        "state": "Shandong"
                    }, 
                    "name": "Qilu Hospital of Shandong university"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jinan", 
                        "country": "China", 
                        "state": "Shandong"
                    }, 
                    "name": "Jinan Infectious Disease Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China", 
                        "state": "Sichuan"
                    }, 
                    "name": "West China Hospital, Sichuan University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Urumqi", 
                        "country": "China", 
                        "state": "Xinjiang"
                    }, 
                    "name": "The First Teaching Hospital of Xinjiang Medical University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China", 
                        "state": "Zhejiang"
                    }, 
                    "name": "Xixi Hospital of Hangzhou"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "302 Military Hospital of China"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "General Hospital of Beijing Military Region"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "Beijing Ditan Hospital, Capital Medical University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "Beijing Youan Hospital, Capital Medical University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "Peking Union Medical College Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "Peking University First Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China"
                    }, 
                    "name": "Daping Hospital, Research Institute of Surgery Third Military Medical University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "Shanghai Public Health Clinical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "Ruijing Hospital, Shanghai Jiaotong University School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China"
                    }, 
                    "name": "Tianjin Infectious Disease Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "4", 
        "official_title": "Phase \u2161, Multi-center, Randomized, Open-label, Parallel-group, Active Controlled Study for the Efficacy and Safety of Pegylated Recombinant Consensus Interferon Variant Solution for Injection in the Treatment of Chronic Hepatitis C", 
        "overall_official": {
            "affiliation": "Beijing Ditan Hospital, Capital Medical University", 
            "last_name": "Cheng jun, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "defined as the proportion of patients who had undetectable plasma HCV RNA at weeks 12", 
            "measure": "cEVR (complete early virologic response)", 
            "safety_issue": "No", 
            "time_frame": "weeks 12  of study therapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01908335"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Beijing Kawin Technology Share-Holding Co., Ltd.", 
            "investigator_full_name": "Cheng  jun", 
            "investigator_title": "vice president", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of patients who had undetectable plasma HCV RNA", 
                "safety_issue": "No", 
                "time_frame": "weeks 4, 24, 48 of study therapy and 24 weeks after the end of treatment"
            }, 
            {
                "measure": "HCV RNA load reduction", 
                "safety_issue": "No", 
                "time_frame": "weeks 4, 12, 24, 48 of study therapy and 24 weeks after the end of treatment"
            }, 
            {
                "description": "defined as the proportion of patients who had undetectable plasma HCV RNA at weeks 4 and 12", 
                "measure": "eRVR ( extended rapid virologic response)", 
                "safety_issue": "No", 
                "time_frame": "weeks 4 and 12 of study therapy"
            }, 
            {
                "description": "defined as the proportion of patients who had detectable plasma HCV RNA at any point during treatment after virological response( undetectable plasma HCV RNA)", 
                "measure": "Breakthrough", 
                "safety_issue": "No", 
                "time_frame": "weeks 24, 48 of study therapy"
            }, 
            {
                "description": "defined as the proportion of patients who had undetectable HCV RNA at the end of treatment, but reappearance of HCV RNA after then", 
                "measure": "Relapse", 
                "safety_issue": "No", 
                "time_frame": "12 and 24 weeks after the end of treatment"
            }
        ], 
        "source": "Beijing Kawin Technology Share-Holding Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Beijing Kawin Technology Share-Holding Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}